Another Watertown Biotech Goes Public and the Commonwealth Claws Back Hiring Tax Credits
Plus pre-clinical data results and more!
Watertown's First Potential IPO since 2023, Remix's Positive Clinical Trial Results, and Triveni Jumps into the Eczema Market
Plus the initial dosing of Enanta and Avencell's Clinical Trials
Kestrel's $1.45 billion AbbVie Deal, FDA Approves First Ever PROTAC, and Werewolf Breaks Arsenal Lease.
Plus more details on Windgap's big pharma partnership and a number of people moves.
Watertown Journal Club - Posterpalooza
Two big conferences last month generated a flurry of posters from Watertown biotechs
ALS TDI moves to Arsenal Yards, Windgap Medical’s Big Pharma Collab, and Watertown’s Q1 fundraising numbers
Plus the initial dosing of Enanta Plus Addgene’s rebrand and Earth Day clean upsAvencell's Clinical Trials
C4's Partnership with Roche, Gilead Options Kymera degrader, and Astellas Licenses Dyno Capsid
Plus the initial dosing of Enanta and Avencell's Clinical Trials
Watertown Journal Club - Improving Vaccine Immunogenicity with Corner Therapeutics
the very model of a modern adjuvant general
Triveni's New Digs, 99 Coolidge's Tenant Bonanza, and Remix's FDA Fast Track Designation
Plus Addgenes' new partnership, and Neumora and Acrivon's cash flow updates
Parallel Bio's Expansion into Therapeutics, and We're Looking Out for More Potential Cash Flow Challenges -Watertown Bio News RoundUp
Plus, where key opinion leaders see Watertown's biotech sector heading.
Watertown Journal Club - Exploring the oRNA behind ORNA Therapeutics
Circular RNAs take center stage
Watertown's Emerging Rare Blood Disorder Therapy Cluster, Warning Signs For Werewolf, and Fallout for Disc Medicines-Watertown Bio News RoundUp
Join us next week in Charting Watertown’s Life Science Future
An FDA Rejection, A Big Pharma Purchase, and Charting Watertown's Life Science Future -Watertown Bio News RoundUp
Plus another $10 million in VC raised, Souffle inks a partnership with Bayer, and more
All About Watertown's VC Funding
2025 Funding numbers are in, 2026 early raises, Lyra Therapeutics runs out of time and more
Watertown Bio Journal Club: How Targeted is Targeted Protein Degradation?
Evaluating the potential impact of off-target degradation of KT-474
What we're looking forward to in 2026
Neumora's positive clinical data , new tenants at the Arsenal, and more
Kymera and Psithera's Funding Haul
A Multi-Million dollar public offering, the developing race for a dupilumab alternative, business awards, and more.
Watertown Bio Journal Club: Engineering Plastic Eating- and Concrete Laying Bacteria
Plus, How to design a PROTAC
Cultivarium's Next Steps
Stratus Therapeutics winding down, Consider the ALS TDI for Giving Tuesday, and more